Meeting
2012 ASCO Annual Meeting
Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).
Authors
Paul Hamberg
Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, Netherlands
Paul Hamberg , Marye Boers-Sonderen , Walter J. Loos , Maja J. De Jonge , Winette T.A. Van Der Graaf , Ben B Suttle , Ferry Eskens , Jaap Verweij , Carla Van Herpen , Stefan Sleijfer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Track
Developmental Therapeutics
Sub Track
Pharmacology
Clinical Trial Registration Number
NTR2063
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2593)
DOI
10.1200/jco.2012.30.15_suppl.2593
Abstract #
2593
Poster Bd #
8B
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.
First Author: Gary Edward Richardson
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2016 ASCO Annual Meeting
A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
First Author: Todd Michael Bauer
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer